Screener / SEC EDGAR /CIK 0000873303 /10-K filed Mar 2, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Sarepta Therapeutics, Inc. SRPT

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Mar 2, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

12.2% to -37.5% (-49.7 pts)

The MD&A has no sentence that names a cause for this change.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-403.3%

The MD&A has no sentence that names a cause for this change.

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+4.3%

“$72.1 million increase in deferred revenue primarily related to the timing of billings to Roche for orders of ELEVIDYS not yet shipped, partially offset by the recognition of collaboration revenue related to the expiration of an option for a certain program previously recorded as deferred revenue; and”

Read it in the 10-K

“$32.2 million decrease in deferred revenue primarily related to the collaboration with Roche.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +4.3%

    “$72.1 million increase in deferred revenue primarily related to the timing of billings to Roche for orders of ELEVIDYS not yet shipped, partially offset by the recognition of collaboration revenue related to the expiration of an option for a certain program previously recorded as deferred revenue; and”

    Read it in the FY 2025 10-K

    “$32.2 million decrease in deferred revenue primarily related to the collaboration with Roche.”

    Read it in the FY 2025 10-K
  • FY 2024 +56.2%

    “$32.2 million decrease in deferred revenue primarily related to the collaboration with Roche.”

    Read it in the FY 2024 10-K

    “$86.8 million decrease in deferred revenue primarily related to the collaboration with Roche;”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 -49.7 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +35.6 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRPT/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.